BETA
Develops and markets pulsed electromagnetic field healing abutments for dental implants, with clinical research in implant stability and peri-implantitis.
MagDent is an Israeli medical device company based in Bnei Brak, led by CEO Benny Barak. Founders Shlomo Barak and Moshe Neuman serve as chairman and technology director, respectively. LinkedIn lists 2011 as the founding year; other directory records differ.
Its Miniaturized Electromagnetic Device (MED) incorporates a battery, electronics and coil in a healing abutment. Model-specific versions fit compatible dental implants and are activated before placement. The company markets the system for implant healing and peri-implant tissue applications.
Published studies evaluate early implant stability and adjunctive nonsurgical peri-implantitis treatment. Supplier listings document channels in Australia and Poland. Dentalcorp’s June 2026 announcement described a US$150,000 SAFE investment commitment and a potential pilot, without confirming a practice rollout. U.S. marketing authorization was not established in this review.
Magdent markets its electromagnetic healing-abutment system internationally and reports CE marking. No Magdent-specific U.S. marketing authorization or product-specific exemption was established. Authorizations for other electromagnetic bone-growth devices cannot be assigned to this dental product. [11][14][1]
No matching FDA recall event was identified in the completed company/applicant, linked-identifier and product-name searches. [6][4]
Latest recorded source review: 2026-10-20.
Scope: selected product families.
Documented commercial product families.
Single-use, implant-specific healing abutment containing a battery, electronics and coil. A separate activator initiates a pulsed electromagnetic field for up to 30 days. [14][13][12][9][16][15][17][2]
Marketed · regulatory scope variesManufacturer and supplier listings in multiple markets; compatibility must be checked for the specific implant model. U.S. availability not established.
Publicly documented relationships; coverage may be incomplete.
| Partner | Territory / scope | Products |
|---|---|---|
| BioMeDent [8] | Australia | Magdent-MED healing abutments and accessories |
| Gursk Medica [19] | Poland | Magdent-MED healing abutments and accessories |
Sources checked October 17, 2026.
Dentalcorp selected Magdent at its Orlando event and announced a US$150,000 SAFE investment commitment subject to terms. A potential pilot was offered; completed financing and a network rollout were not established. [18]
A multicenter retrospective-prospective analysis included 33 patients and 47 implants, with 12–26-month follow-up. Authors reported clinical improvements and called for larger studies; founder involvement was disclosed. Print publication followed in April 2026. [17]
Randomized double-blind pilot included 23 patients and 34 implants, comparing debridement with active or inactive PEMF over three months. Results were preliminary and population-specific. [15]
A 19-participant, 40-implant study compared active MED and sham abutments over 12 weeks. Early stability findings support further investigation; company device support and author affiliations were disclosed. [16]
Company LinkedIn lists 2011. Some secondary directories use 2010; year remains subject to company confirmation. [9]
Accessed 10/20/2026